Amicar (Aminocaproic Acid Oral Liquid) and Thrombohemorrhagic disorders
Result of checking the interaction of drug Amicar (Aminocaproic Acid Oral Liquid) and disease Thrombohemorrhagic disorders for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:The use of aminocaproic acid is contraindicated in patients with active intravascular clotting. Aminocaproic acid should not be used in the presence of disseminated intravascular coagulation (DIC) without concomitant administration of heparin. Aminocaproic acid inhibits plasminogen activators and, to a lesser extent, plasmin activity, resulting in decreased fibrinolysis. Clinical monitoring of clot lysis activity and fibrinolytic determinants (profibrinolysin, fibrinolysin and anti-fibrinolysin) is recommended.
- "Product Information. Amicar (aminocaproic acid)." Immunex Corporation, Seattle, WA.
Generic Name: aminocaproic acid
Brand Name: Amicar
Synonyms: Amicar